2.35
0.00 (0.00%)
| Previous Close | 2.35 |
| Open | 2.30 |
| Volume | 49,820 |
| Avg. Volume (3M) | 54,712 |
| Market Cap | 87,871,400 |
| Price / Sales | 1.64 |
| Price / Book | 4.62 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Profit Margin | -34.33% |
| Operating Margin (TTM) | -44.22% |
| Diluted EPS (TTM) | -0.680 |
| Quarterly Revenue Growth (YOY) | -9.10% |
| Total Debt/Equity (MRQ) | 36.23% |
| Current Ratio (MRQ) | 1.74 |
| Operating Cash Flow (TTM) | -14.91 M |
| Levered Free Cash Flow (TTM) | -10.11 M |
| Return on Assets (TTM) | -16.54% |
| Return on Equity (TTM) | -49.28% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Distribution (US) | Bullish | Bullish |
| Medical Distribution (Global) | Bullish | Bullish | |
| Stock | EDAP TMS S.A. | - | - |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 4.0 |
| Average | 1.88 |
|
Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others. |
|
| Sector | Healthcare |
| Industry | Medical Distribution |
| Investment Style | Small Value |
| % Held by Institutions | 41.46% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bruce & Co., Inc. | 30 Sep 2025 | 438,652 |
| Cahill Financial Advisors Inc | 30 Sep 2025 | 134,960 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 20 Nov 2025 | Announcement | EDAP Receives FDA 510(k) Clearance for Latest Evolution of Focal One Robotic HIFU |
| 18 Nov 2025 | Announcement | EDAP to Present at Piper Sandler 37th Annual Healthcare Conference |
| 06 Nov 2025 | Announcement | EDAP Reports Third Quarter 2025 Financial Results |
| 04 Nov 2025 | Announcement | EDAP to Present at Jefferies Global Healthcare Conference in London |
| 27 Oct 2025 | Announcement | EDAP to Participate in the UBS Global Healthcare Conference |
| 23 Oct 2025 | Announcement | EDAP to Announce Third Quarter 2025 Financial Results on November 6, 2025 |
| 20 Oct 2025 | Announcement | EDAP Secures €36 Million Credit Facility from European Investment Bank to Accelerate Growth of Focal One® Robotic HIFU |
| 17 Oct 2025 | Announcement | Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |